CJC-1295 + DAC
CJC-1295 + DAC is a synthetic tetrasubstituted analogue of Growth Hormone-Releasing Hormone (GHRH) consisting of 29 amino acids. It is modified with a Drug Affinity Complex (DAC), specifically a maleimidoproprionic acid group, which allows it to chemically bond with serum albumin. Research investigates this mechanism for its potential to significantly extend the peptide's biological half-life and stability compared to native GHRH. For Research Use Only. Not for human consumption.
CJC-1295 + DAC is a modified peptide with the molecular formula C₁₆₅H₂₆₉N₄₇O₄₆. It is based on the first 29 amino acids of the endogenous Growth Hormone-Releasing Hormone (GHRH), with specific amino acid substitutions at positions 2, 8, 15, and 27 to enhance resistance to enzymatic cleavage. The distinguishing feature of this compound is the addition of a Drug Affinity Complex (DAC) at the lysine residue, which facilitates bioconjugation with circulating serum albumin.
Scientific studies focus heavily on the pharmacokinetics of this conjugation. By binding to albumin, the peptide is protected from rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance. Research in animal models has demonstrated that this mechanism can extend the plasma half-life of the compound from minutes to several days, maintaining stable concentrations in the bloodstream.
In laboratory settings, CJC-1295 + DAC is utilized to investigate the pulsatile secretion of growth hormone. Unlike continuous infusion models, the albumin-bound complex allows researchers to observe sustained receptor activation. Studies in murine and canine models have documented its effects on total pituitary RNA and protein synthesis, providing data on long-term GHRH receptor stimulation.
This product is strictly for laboratory and research purposes only. CJC-1295 + DAC is not intended for human use, diagnostic, or therapeutic procedures. It serves as a reagent for scientific study and method development.
References
- Teichman, S. L., et al. (2006). “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
- Jette, L., et al. (2005). “Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog.” Endocrinology, 146(7), 3052-3058.
- Sackmann-Sala, L., et al. (2009). “Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.” Growth Hormone & IGF Research, 19(6), 471-477.